Mariana Varga, MD
Neurology · Oklahoma City, OKNPI 1962542225
Payments from drug & device makers
Across 1,405 payments — averaging $476.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sage Therapeutics, LLC$369K
- AbbVie$57K
- MDD US Operations, LLC$47K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$45K
- Abbott$33K
- Neurocrine Biosciences, Inc.$27K
- plus $92K from 25 others
What the payments were for
- Consulting fees$26,11414%
- Speaking & faculty fees$121,69366%
- Travel & lodging$11,7416%
- Food & beverage$23,84613%
- Education$990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sage Therapeutics, LLC | 13 | $369,265 |
| AbbVie(2 entities) | 50 | $56,612 |
| MDD US Operations, LLC | 135 | $47,169 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $45,225 |
| Abbott | 295 | $32,786 |
| Neurocrine Biosciences, Inc. | 104 | $26,596 |
| Adamas Pharmaceuticals, Inc. | 19 | $18,197 |
| Teva Pharmaceuticals USA, Inc. | 80 | $16,515 |
| Acorda Therapeutics, Inc | 36 | $16,142 |
| Medtronic(2 entities) | 223 | $11,587 |
| Lundbeck LLC | 30 | $11,085 |
| Amneal Pharmaceuticals LLC | 71 | $7,806 |
| Sunovion Pharmaceuticals Inc. | 18 | $3,506 |
| Boston Scientific | 89 | $2,937 |
| Acadia Pharmaceuticals Inc | 142 | $1,628 |
| UCB, Inc. | 2 | $769 |
| Kyowa Kirin, Inc. | 23 | $429 |
| Merz North America, Inc. | 7 | $221 |
| Biogen | 4 | $177 |
| Microtransponder, Inc. | 1 | $157 |
| Avion Pharmaceuticals | 11 | $152 |
| Merz Pharmaceuticals, LLC | 6 | $126 |
| Ipsen Biopharmaceuticals, Inc | 7 | $120 |
| Argenx US, Inc. | 1 | $116 |
| Eisai Inc. | 4 | $96 |
| GE HealthCare | 3 | $89 |
| Arbor Pharmaceuticals, Inc. | 6 | $86 |
| Supernus Pharmaceuticals, Inc. | 2 | $51 |
| Vertical Pharmaceuticals, LLC | 3 | $37 |
| Insightec,inc | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$669,717 in reported general payments places this provider in the 95th percentile of 152 neurology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 88 | $526,393 |
| Austedo XrDeutetrabenazine | 25 | $385,239 |
| AustedoDeutetrabenazine | 51 | $321,616 |
| RytaryCarbidopa/Levodopa | 368 | $207,789 |
| GocovriAmantadine Hcl | 50 | $156,188 |
| Rasagiline Mesylate | 543 | $91,994 |
| Droxidopa | 37 | $91,940 |
| BotoxOnabotulinumtoxina | 51 | $76,131 |
| OngentysOpicapone | 32 | $49,442 |
| XadagoSafinamide Mesylate | 27 | $42,999 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 953 | $36,500 |
| AzilectRasagiline Mesylate | 12 | $35,558 |
| XeominIncobotulinumtoxina | 13 | $17,283 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 358 | $9,659 |
| Primidone | 244 | $6,546 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $16,515 | $706,85676 claims |
| Acadia Pharmaceuticals IncNuplazid | $1,628 | $526,39388 claims |
| Amneal Pharmaceuticals LLCRytary | $7,806 | $207,789368 claims |
| MDD US Operations, LLCGocovri | $47,169 | $156,18850 claims |
| AbbVieBotox | $56,612 | $76,13151 claims |
| Neurocrine Biosciences, Inc.Ongentys | $26,596 | $49,44232 claims |
| Merz North America, Inc.Xeomin | $221 | $17,28313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 152 neurology providers in Oklahoma.
Other neurology in Oklahoma City
- Gabriel PardoOklahoma City$10.3M
- Cherian KarunapuzhaOklahoma City$4.1M
- James BattisteOklahoma City$1.1M
- Marguerite ButcheeOklahoma City$324K
- Chelsea BerkleyOklahoma City$277K
- Evgeny SidorovOklahoma City$212K
- Aaron FarrowOklahoma City$172K
- Ashish MasihOklahoma City$168K
- Erika Santos HortaOklahoma City$93K
- Christi PendergraftOklahoma City$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.